Psoriasis and metabolic syndrome

Journal of Dermatology

Volumn 39, Issue 3, 2012, Pages 212-218

  Takahashi, Hidetoshi ^a   Iizuka, Hajime ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

comorbidities; metabolic syndrome; psoriasis

Indexed keywords

ADIPOCYTOKINE; GAMMA INTERFERON; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

BODY MASS; CARDIOVASCULAR DISEASE; DYSLIPIDEMIA; ETHNICITY; HEART INFARCTION; HELPER CELL; HYPERTENSION; INSULIN RESISTANCE; METABOLIC SYNDROME X; OBESITY; PSORIASIS; REVIEW;

ADIPONECTIN; ANTIBODIES, MONOCLONAL, HUMANIZED; CARDIOVASCULAR DISEASES; COMORBIDITY; DIABETES MELLITUS; HUMANS; HYPERTENSION; IMMUNOLOGIC FACTORS; METABOLIC SYNDROME X; OBESITY; PSORIASIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84857641408     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2011.01408.x     Document Type: Review

References (104)

1. Myers WA, Gottliep AB, Maase P,. Psoriasis and psoriatic arthritis: clinical features and disease mechanism. Clin Dermatol 2006; 24: 438-447. (Pubitemid 44332869)
2. Langley RG, Krueger GG, Griffiths CE,. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis 2005; 64 (Suppl): 18-23.
3. Takahashi H, Nakamura K, Kaneko F, et al. Analysis of psoriasis patients registered in Japanese Society for Psoriasis research from 2002 to 2008. J Dermatol (in press).
4. Griffiths C, Camp R, Barker J,. Psoriasis. In:, Champion RH, Burton JL, Burn DA, Breathnach SM, eds. Textbook of Dermatology, 7th edn, Vol. 2. Oxford: Blackwell Science Publications, 2004; 35.1-35.69.
5. Christophers E, Mrowietz U,. Psoriasis. In:, Freedberg IM, Eisen AZ, Wolf K, et al. Fitzpatrick's Dermatology in General Medicine, 6th edn. New York: McGraw Hill, 2003; 407-435.
6. Raychaundhuri SP, Gros J,. A comparative study of pediatric onset psoriasis with adult onset psoriasis. Pediatr Dermatol 2000; 17: 174-178.
7. Park HS, Park JY, Yu R,. Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-alpha and IL-6. Diabetes Res Clin Pract 2005; 69: 29-35. (Pubitemid 40813409)
8. Panagiotakos DB, Pitsavos C, Yannakoulia M, et al. The implication of obesity and central fat on markers of chronic inflammation: the ATTICA study. Atherosclerosis 2005; 183: 308-315. (Pubitemid 41579282)
9. Vettor R, Milan G, Rossato M, Federspil G,. Review article: adipocytokines and insulin resistance. Aliment Pharmacol Ther 2005; 22 (Suppl 2): 3-10. (Pubitemid 41564373)
10. Franks PW, Brage S, Laun J, et al. Leptin predicts a worsening of the features of the metabolic syndrome independently of obesity. Obes Res 2005; 13: 1476-1484.
11. Correia ML, Rahmouni K,. Role of leptin in the cardiovascular and endocrine complications of metabolic syndrome. Diabetes Obes Metab 2006; 8: 603-610. (Pubitemid 44515557)
12. Mojiminiyi OA, Abdella NA, Al Arouji M, Ben Nakhi A,. Adiponectin, insulin resistance and clinical expression of the metabolic syndrome in patients with type 2 diabetes. Int J Obes (Lond) 2007; 3: 213-220. (Pubitemid 46188199)
13. Patel DA, Srinivasan SR, Xu JH, et al. Adiponectin and its correlates of cardiovascular risk in young adults: The Bogalusa Heart Study. Metabolism 2006; 55: 1551-1557. (Pubitemid 44537354)
14. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421.
15. Matsunaga Y,. Therapy insight: adipocytokines in metabolic syndrome and related cardiovascular disease. Nat Clin Pract Cardiovasc Med 2006; 3: 35-42.
16. Lemieux I, Pascot A, Couillsrd C, et al. Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation 2000; 102: 179-184. (Pubitemid 30451774)
17. Carr DB, Utzschneider KM, Hull RL, et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 2004; 53: 2087-2094. (Pubitemid 38970759)
18. Henseler T, Christophers E,. Disease concomitance in psoriasis. J Am Acad Dermatol 1995; 32: 982-986.
19. Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006; 55: 829-835. (Pubitemid 44556851)
20. Mallbis L, Ritchen CT, Stahl M,. Metabolic disorders in patients with psoriasis and psoriatis arthritis. Curr Rheumatol Rep 2006; 8: 355-363.
21. Mallbris L, Akre O, Granath F, et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004; 19: 225-230. (Pubitemid 38461682)
22. Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296: 1735-1741. (Pubitemid 44547793)
23. Wakkee M, Thio HB, Prens DB, et al. Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. Atherosclerosis 2007; 190: 1-9. (Pubitemid 44908334)
24. Gisondi P, Tessari G, Conti A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007; 157: 68-73. (Pubitemid 46934281)
25. Reaven GM,. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607. (Pubitemid 19004941)
26. Kaplan NM,. The deadly quartet: upper body obesity, glucose intolerance, hypertriglyceridemia and hypertension. Arch Intern Med 1989; 149: 1514-1520. (Pubitemid 19177621)
27. DeFronzo RA, Ferrannini E,. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1992; 14: 173-194.
28. Nakamura T, Tokunaga K,. Contribution of visceral fat accumulation to the development of coronary artery disease in non-obese men. Atherosclerosis 1994; 107: 239-246. (Pubitemid 24206863)
29. Lamarche B, Tchernof A, Mauriège P, et al. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA 1998; 16: 442-443.
30. World Health Organization. Definition, Diagnosis, and Classification of Diabetes Mellitus and its Complications: Report of a WHO Consultation. Geneva: World Health Organization, 1999.
31. Ford ES, Giles WH, Dietz WH,. Prevalence of metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-359. (Pubitemid 34251969)
32. Schlaak JF, Buslau M, Jochum W, et al. T cells involved in psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol 1994; 102: 145-149. (Pubitemid 24060399)
33. Krueger JG,. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002; 46: 1-23. (Pubitemid 34073472)
34. Nicholoff BJ, Nestle FO,. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 2004; 113: 1664-1675. (Pubitemid 39071656)
35. Fitch JG, Harper E, Skorcheva I, et al. Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines. Curr Rheumatol Rep 2007; 9: 461-467. (Pubitemid 350305203)
36. Chamian F, Krueger JG,. Psoriasis vulgaris: an interplay of T lymphocytes, dendritic cells, and inflammatory cytokines in pathogenesis. Curr Opin Rheumatol 2004; 16: 331-337. (Pubitemid 38803131)
37. Rocha-Pereria P, Santos-Silva A, Rebelo I, et al. The inflammatory response in mild and in severe psoriasis. Br J Dermatol 2004; 150: 917-928. (Pubitemid 38903524)
38. Terui T, Ozawa M, Tagami H,. Role of neutrophils in induction of acute inflammatory in T-cells-mediated immune dermatosis, psoriasis: a neurtophil-associated inflammation-boosting loop. Exp Dermatol 2000; 9: 1-10. (Pubitemid 30093030)
39. Sommer DM, Jenisch S, Suchan M, et al. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006; 298: 321-328.
40. Cohen AD, Gilutz H, Henkin Y, et al. Psoriasis and the metabolic syndrome. Acta Derm Venereol 2007; 87: 506-509. (Pubitemid 351373394)
41. Cohen AD, Sherf M, Vidavsky L, et al. Association between psoriasis and the metabolic syndrome. Dermatology 2008; 216: 152-155.
42. Chen YJ, Wu CY, Shen JL, et al. Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome. Arch Dermatol 2008; 144: 1571-1575.
43. Takahashi H, Takahashi I, Honma M, et al. The prevalence of metabolic syndrome in the Japanese psoriasis patients. J Dermatol Sci 2010; 57: 143-144.
44. Love TJ, Qureshi AA, Karlson EW, et al. Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition examination survey, 2003-2006. Arch Dermatol 2011; 147: 419-425.
45. Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006; 288: 1549-1555.
46. Flegal KM, Carrol MD, Ogden CL, Johnson CL,. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002; 288: 1723-1727.
47. World Health Organization. Obesity in Europe. Available at:.
48. Herron MD, Hinckley M, Hoffman MS, et al. The impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 2005; 141: 1527-1534. (Pubitemid 41815842)
49. Mallbris L, Granath F, Hamstem A, Stahle M,. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol 2006; 54: 614-621.
50. Naldi L, Chatenoud L, Linder D,. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005; 125: 61-67. (Pubitemid 40981424)
51. Setty AR, Curhan G, Choi HK,. Obesity, waist circumference, weight change, and the wrist of psoriasis in women. Arch Intern Med 2007; 167: 1670-1675.
52. Wolters M,. Diet and psoriasis: experimental dada and clinical evidence. Br J Dermatol 2005; 153: 706-714. (Pubitemid 41415895)
53. Sterry W, Strober BE, Menter A,. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol 2007; 157: 649-655. (Pubitemid 47389868)
54. Takahashi H, Tsuji H, Takahashi I, et al. Prevalence of obesity/adiposity in Japanese psoriasis patients: adiposity is correlated with the severity of psoriasis. J Dermatol Sci 2009; 55: 74-76.
55. Seckin D, Tokgozoglu L, Akkaya S,. Are lipoprotein profile and lipoprotein (a) levels altered in men with psoriasis? J Am Acad Dermatol 1944; 31: 445-449.
56. Lindegard B,. Diseases associated with psoriasis in a general population of 159,200 middle-aged urban, native Swedes. Dermatologica 1986; 172: 298-304. (Pubitemid 16014779)
57. Qureshi AA, Choi HK, Setty AR, Curhan GC,. Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses. Arch Dermatol 2009; 145: 379-382.
58. Brauchli YB, Jick SS, Meier CR,. Psoriasis and the risk of incident diabetes mellitus: a population-based study. Br J Dermatol 2008; 159: 1331-1337.
59. Rocha-Pereira P, Santos-Silva A, Rebelo I, et al. Dyslipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease. Clin Chim Acta 2001; 303: 33-39. (Pubitemid 32121803)
60. Seishima M, Sishima M, Mori S, Noma A,. Serum lipid and apolipoprotein levels in patients with psoriasis. Br J Dermatol 1994; 130: 738-742. (Pubitemid 24218665)
61. Uyanik BS, Ari Z, Onur E, et al. Serum lipids and apolipoprotein in patients with psoriasis. Clin Chem Lab Med 2002; 40: 65-68. (Pubitemid 34196452)
62. Vanizor Kural B, Oren A, Cimşit G, et al. Evaluation of the atherogenic tendency of lipids and lipoprotein content and their relationships with oxidant-antioxidant system in patients with psoriasis. Clin Chem Acta 2003; 328: 71-82. (Pubitemid 36135781)
63. Pietrzak A, Lecewicz-Torun B,. Activity of serum lipase and the diversity of serum lipid profile in psoriasis. Med Sci Monit 2002; 8: CR9-CR13. (Pubitemid 34136316)
64. Cimsit G, Oren A, Deger O,. The variation of serum lipoprotein (a) level with disease activity in psoriasis. Br J Dermatol 1998; 138: 917-919.
65. Zhang HH, Halbleib M, Ahmad F, et al. Tumor necrosis factor-alpha stimulates lipolysis in differentiated human adipocytes through activation of extracellular signal-related kinase and elevation of intracellular cAMP. Diabetes 2002; 51: 2929-2935.
66. Van Hall G, Steensberg A, Sacchetti M, et al. Interleukin-6 stimulates lipolysis and fat oxidation in humans. J Clin Endocrinol Metab 2003; 88: 3005-3010. (Pubitemid 36877463)
67. Ena P, Madeddu P, Glorioso N, et al. High prevalence of cardiovascular diseases and enhanced activity of the renin-angiotensin system in psoriatic patients. Acta Cardiol 1985; 40: 199-205.
68. Das UN,. Is angiotensin-II an endogeneous pro-inflammatory molecule? Med Sci Monit 2005; 11: RA155-RA162.
69. Christophers E,. Psoriasis-epidemiology and clinical spectrum. Clin Exp Dermatol 2001; 26: 314-320.
70. McDonald CJ, Calabresi P,. Psoriasis and occlusive vascular diease. Br J Dermatol 1978; 99: 469-475.
71. Krueger GG, Duvic M,. Epidemiology of psoriasis: clinical issues. J Invest Dermatol 1994; 102: 14S-18S. (Pubitemid 24210359)
72. Brauchli YB, Jick SS, Miret M, Meier CR,. Psoriasis and the risk of incident myocardial infarction, stroke or transient ischemic attack: an inception cohort study with a nested case-control analysis. Br J Dermatol 2009; 160: 1048-1056.
73. Guerre-Millo M,. Adipose tissue and adipokines: for better or worse. Diabetes Metab 2004; 30: 13-19.
74. Ronti T, Lupattelli G, Mannarino E,. The endocrine function of adipose tissue: an update. Clin Endocrinol (Oxf) 2006; 64: 355-365.
75. Cnop M, Havel PJ, Utzschneider KM, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Dermatologica 2003; 46: 231-244.
76. Hug C, Lodish HF,. The role of the adipocyte hormone adiponectin in cardiovascular disease. Curr Opin Pharmacol 2005; 5: 129-134. (Pubitemid 40378742)
77. Scherer PE,. Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes 2006; 55: 1537-1545. (Pubitemid 44324105)
78. Matsuzaka Y,. The metabolic syndrome and adipocytokines. FEBS Lett 2006; 580: 2917-2921.
79. Ryo M, Nakamura T, Kihara S, et al. Adiponectin as a biomarker of metabolic syndrome. Circ J 2004; 68: 975-981.
80. Hulthe J, Hulten LM, Fagerberg B,. Low adipocyte-derived plasma protein adinonectin concentrations are associated with metabolic syndrome and small dense low-density lipoprotein particles: atherosclerosis and insulin resistance study. Metabolism 2003; 52: 1612-1614. (Pubitemid 38049281)
81. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin in obese. Biochem Biophys Res Commun 1999; 257: 79-83. (Pubitemid 29299050)
82. Fantuzzi G,. Adiponectin and inflammation: consensus and controversy. Allergy Clin Immunol 2008; 121: 326-330.
83. Okamoto Y, Kihara S, Funahashi T, et al. Adiponectin: a key adipocytokine in metabolic syndrome. Clin Sci (Lond) 2006; 110: 267-278. (Pubitemid 43341630)
84. Iwashima Y, Katsuya T, Ishikawa K, et al. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 2004; 43: 1318-1323. (Pubitemid 38691756)
85. Kaur S, Zilmer K, Kairane C, et al. Clear differences in adiponectin level and glutathione redox status revealed in obese and normal-weight patients with psoriasis. Br J Dermatol 2008; 159: 1364-1367.
86. Takahashi H, Tsuji H, Takahashi I, et al. Plasma adiponectin and leptin levels in Japanese patients with psoriasis. Br J Dermatol 2008; 159: 1207-1208.
87. Shibata S, Saeki H, Tada Y, et al. Psoriasis arthropathica associated with severe obesity showing high serum leptin level. J Dermatol Sci 2009; 55: 62-63.
88. Takahashi H, Honma M, Ishida-Yamamoto A, Iizuka H,. Adiponectin and leptin modulate cell proliferation and cytokine secretion of normal human keratinocytes and T lymphocytes. J Dermatol Sci 2010; 59: 143-145.
89. Campfield LA, Smith FJ, Guisez Y, et al. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science 1995; 269: 546-549.
90. Flier JS,. Leptin expression and action: new experimental paradigms. Proc Natl Acad Sci USA 1997; 94: 4242-4245. (Pubitemid 27194225)
91. Considine RV, Sinha MK, Heiman MI, et al. Serum immunoreactive leptin concentrations in normal-weight and obese humans. N Engl J Med 1996; 365: 292-295. (Pubitemid 26033933)
92. Hegyi K, Fulop K, Kovacs K, et al. Leptin-induced signal transduction pathways. Cell Biol Int 2004; 28: 159-169. (Pubitemid 38230226)
93. Ciccone M, Vettor R, Pannacciulli N, et al. Plasma leptin is independently associated with the intima-media thickness of the common carotid artery. Int J Obes Relat Metab Disord 2001; 25: 805-810. (Pubitemid 32601372)
94. Wolk R, Berger P, Lennon RJ, et al. Plasma leptin and prognosis in patients with established coronary atherosclerosis. J Am Coll Cardiol 2004; 44: 1819-1824. (Pubitemid 39424081)
95. Wallace AM, McMahon A, Packard CJ, et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation 2004; 44: 1819-1824.
96. Johnston A, Arnadottir S, Gudjonsson JE, et al. Obesity in psoriasis: leptin and resistin as mediators of cutaneous inflammation. Br J Dermatol 2008; 159: 342-350. (Pubitemid 352009847)
97. Wang Y, Chen J, Zhao Y, et al. Psoriasis is associated with increased levels of serum leptin. Br J Dermatol 2008; 158: 1134-1135. (Pubitemid 351521426)
98. Takahashi H, Tsuji H, Hashimoto Y, et al. Serum cytokines and growth factor levels in Japanese psoriasis patients. Clin Exp Dermatol 2010; 35: 645-649.
99. Boehncke WH, Boehncke S, Tobin AM, Kirby B,. The 'psoriatic march': a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol 2011; 20: 303-307.
100. Cauza E, Cauza K, Hanusch-Enserer U, et al. Intravenous anti-TNF-alpha antibody therapy leads to elevated triglyceride and reduced HDH-cholesterol levels in psoriasis with rheumatoid and psoriatic arthritis. Wien Klin Wochenschr 2002; 114: 1004-1007. (Pubitemid 36105546)
101. Dahlqvist SR, Engstrand S, Berblin E, Johnson O,. Convention towards an atherogenetic lipid profile in rheumatoid arthritis patients during long-term infliximab therapy. Scand J Rheumatol 2006; 35: 107-111.
102. Bernstein LE, Berry J, Kim S, et al. Effect of eternercept in patients with metabolic syndrome. Arch Intern Med 2006; 166: 902-908.
103. Jacobsson LT, Turesson C, Gülfe A, et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005; 32: 1213-1218. (Pubitemid 40995372)
104. Strober B, Berger E, Cather J, et al. A series of critically challenging case scenarios in moderate to severe psoriasis: a Delphi consensus approach. J Am Acad Dermatol 2009; 61: S1-S46.